{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:52Z","timestamp":1791379492285,"version":"4.3.2"},"reference-count":70,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety of causes. The number one cause is medication-related\u2014common ones including sulfonamides, antiepileptics, allopurinol, and nonsteroidal anti-inflammatory drugs. Genetics also play a role as several human leukocyte antigen (HLA) genotypes within certain ethnic groups have been implicated in adverse reactions to specific drugs. HLAB*15:02 has been identified in the Chinese and others of Southeast Asian origin to increase susceptibility to lamotrigine and carbamazepine-induced SJS. Furthermore, patients of Japanese origin with HLAB*31:01 and Koreans with HLA-B*44:03 are also at increased risk of SJS after receiving the same two drugs. Of the antiepileptics, one most commonly associated with SJS is lamotrigine, a pre-synaptic voltage-gated sodium channel inhibitor. Lamotrigine is an antiepileptic drug of the phenyltriazine class that is indicated for the prevention of focal and generalized seizures in epileptic patients as well as monotherapy or adjunctive maintenance treatment for Bipolar disorder. The occurrence of SJS is not a rigid contraindication to lamotrigine reintroduction in the same patient. To facilitate this, manufacturers have developed a strict re-challenge dosing regimen to facilitate successful reintroduction of lamotrigine. In order to prevent the recurrence of SJS during a re-challenge, timing of re-dose and initial rash severity must be considered. Therefore, to prevent SJS recurrence, prime lamotrigine re-challenge patients are those with mild initial rash that has not occurred within the previous 4 weeks. The Federal Food and Drug Administration recommends the testing HLA subtypes for those associated with SJS prior to starting lamotrigine.<\/jats:p>","DOI":"10.64719\/pb.4398","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"96-114","source":"Crossref","is-referenced-by-count":19,"title":["Lamotrigine and Stevens-Johnson Syndrome Prevention"],"prefix":"10.64719","volume":"51","author":[{"given":"Amber N.","family":"Edinoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Fitz-Gerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha St","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja A.","family":"Gennuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Davis WD, Schafer PA. Stevens-Johnson syndrome: a challenging diagnosis. Advanced Emergency Nursing Journal. 2018;40(3):176\u2013182.","DOI":"10.1097\/TME.0000000000000197"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Critical Care Medicine. 2011;39(6):1521\u20131532.","DOI":"10.1097\/CCM.0b013e31821201ed"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Alvarado SA, Mu\u00f1oz-Mendoza D, Bahna SL. High-risk drug rashes. Annals of Allergy. Asthma and Immunology. 2018;121(5):552\u2013560.","DOI":"10.1016\/j.anai.2018.05.022"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Medicine. 2008;14(12):1343\u20131350.","DOI":"10.1038\/nm.1884"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. Journal of the American Academy of Dermatology. 2013;69(2):173.e1\u2013173.e13.","DOI":"10.1016\/j.jaad.2013.05.003"},{"key":"ref6","unstructured":"Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, clinical manifestations, and diagnosis\u2014UpToDate."},{"key":"ref7","unstructured":"Ellender RP, Peters CW, Albritton HL, Garcia AJ, Kaye AD. Clinical considerations for epidermal necrolysis. The Ochsner journal. 2014;14(3):413\u2013417."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Eginli A, Shah K, Watkins C, Krishnaswamy G. Stevens-Johnson syndrome and toxic epidermal necrolysis. Annals of Allergy, Asthma and Immunology. 2017","DOI":"10.1016\/j.anai.2016.11.019"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mustafa SS, Ostrov D, Yerly D. Severe Cutaneous Adverse Drug Reactions: presentation, risk factors, and management. Current Allergy and Asthma Reports. 2018;18(4):1\u20139.","DOI":"10.1007\/s11882-018-0778-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG et al. UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016.. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2016","DOI":"10.1016\/j.bjps.2016.01.034"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY. Long-term sequelae of stevens-johnson syndrome\/toxic epidermal necrolysis. Acta Dermato-Venereologica. 2016","DOI":"10.2340\/00015555-2295"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Peter JG, Lehloenya R, Dlamini S, Risma K, White KD, Konvinse KC et al. Severe Delayed Cutaneous and Systemic Reactions to Drugs: a global perspective on the science and art of current practice. Journal of Allergy and Clinical Immunology: In Practice. 2017","DOI":"10.1016\/j.jaip.2017.01.025"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. Journal of Investigative Dermatology. 2016","DOI":"10.1016\/j.jid.2016.03.023"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY et al. Incidence of stevens-johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS ONE. 2016","DOI":"10.1371\/journal.pone.0165933"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. Journal of the American Academy of Dermatology. 2017","DOI":"10.1016\/j.jaad.2017.06.023"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ et al. Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01. The Journal of Immunology. 2014","DOI":"10.4049\/jimmunol.1302306"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012","DOI":"10.1016\/j.molimm.2012.02.048"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clinical and Experimental Immunology. 2000","DOI":"10.1046\/j.1365-2249.2000.01119.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Tohyama M, Watanabe H, Murakami S, Shirakata Y, Sayama K, Iijima M et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology. 2012","DOI":"10.1111\/j.1365-2133.2011.10649.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C et al. TNF-\u03b1 and IFN-\u03b3 are potential inducers of fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. Journal of Investigative Dermatology. 2013","DOI":"10.1038\/jid.2012.330"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"De Araujo E, Dessirier V, Lapr\u00e9e G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN et al. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Experimental Dermatology. 2011","DOI":"10.1111\/j.1600-0625.2010.01176.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology. 2008;58(1):25\u201332.","DOI":"10.1016\/j.jaad.2007.08.036"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC et al. A marker for Stevens-Johnson syndrome. Nature. 2004","DOI":"10.1038\/428486a"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics. 2006","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002","DOI":"10.1016\/S0140-6736(02)08158-8"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jung SO, Cho MJ, Park D Il, Kim SY, Kim JO, Jung SS et al. Stevens-johnson syndrome and hypothermia associated with anti-tuberculosis medication in a patient with heart failure. Chinese Medical Journal. 2015","DOI":"10.4103\/0366-6999.167373"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous Disease and Drug Reactions in HIV Infection. New England Journal of Medicine. 1993","DOI":"10.1056\/NEJM199306103282304"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Okamoto-Uchida Y, Nakamura R, Sai K, Imatoh T, Matsunaga K, Aihara M et al. Effect of infectious diseases on the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biological and Pharmaceutical Bulletin. 2017;40(9):1576\u20131580.","DOI":"10.1248\/bpb.b17-00207"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US food and drug administration adverse event reporting system. Epilepsia. 2018;59(12):2318\u20132324.","DOI":"10.1111\/epi.14591"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Parker G. Risks associated with lamotrigine prescription: a review and personal observations. SAGE Publications Inc. 2018;26:640\u2013642. Australasian Psychiatry.","DOI":"10.1177\/1039856218760733"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T et al. Medication Use and the Risk of Stevens\u2013Johnson Syndrome or Toxic Epidermal Necrolysis. New England Journal of Medicine. 1995;333(24):1600\u20131608.","DOI":"10.1056\/NEJM199512143332404"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Frey N, Bodmer M, Bircher A, R\u00fcegg S, Jick SS, Meier CR et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia. 2017;58(12):2178\u20132185.","DOI":"10.1111\/epi.13925"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Bloom R, Amber KT. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. Anais Brasileiros de Dermatologia. 2017;92(1):139\u2013141.","DOI":"10.1590\/abd1806-4841.20175070"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Halevi A, Ben-Amitai D, Zion Garty B. Toxic epidermal necrolysis associated with acetaminophen ingestion. Annals of Pharmacotherapy [Internet] 2000;34(1):32\u201334. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10669183\/","DOI":"10.1345\/aph.19064"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Trujillo C, Gago C, Ramos S. Stevens-Jonhson syndrome after acetaminophen ingestion, confirmed by challenge test in an eleven-year-old patient. Allergologia et Immunopathologia [Internet] 2010;38(2):99\u2013100. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19875224\/","DOI":"10.1016\/j.aller.2009.06.009"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Leger F, Machet L, Jan V, Machet MC, Lorette G, Vaillant L. Acute generalized exanthematous pustulosis associated with paracetamol [3] [Internet]. Acta Dermato-Venereologica. Acta Derm Venereol. 1998;78(3):222\u2013223. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9602233\/","DOI":"10.1080\/000155598441594"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Bygum A, Gregersen JW, Buus SK. Acetaminophen-induced toxic epidermal necrolysis in a child. Pediatric Dermatology. 2004;21(3):236\u2013238. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15165202\/","DOI":"10.1111\/j.0736-8046.2004.21309.x"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R et al. Causative Drugs of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Israel. The Journal of Clinical Pharmacology. 2017;57(7):823\u2013829.","DOI":"10.1002\/jcph.873"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Parker G. Development of an incipient Stevens-Johnson reaction while on a stable dose of lamotrigine. Australasian Psychiatry. 2016;24(2):193\u2013194.","DOI":"10.1177\/1039856215612993"},{"key":"ref40","unstructured":"Lamictal. 2009:1\u201364. Tablets CD. (lamotrigine) Tablets \u00ae."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. Journal of Clinical Psychopharmacology. 2003;23(5):484\u2013495.","DOI":"10.1097\/01.jcp.0000088915.02635.e8"},{"key":"ref42","unstructured":"Lamotrigine: Drug information\u2014UpToDate."},{"key":"ref43","unstructured":"Lamotrigine\u2014Pharmacological Mechanism of Action & Clinical Application."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Shen YC. Treatment of acute bipolar depression. Tzu Chi Medical Journal. 2018;30(3):141\u2013147. Wolters Kluwer Medknow Publications.","DOI":"10.4103\/tcmj.tcmj_71_18"},{"key":"ref45","unstructured":"Lamictal (Lamotrigine): Uses, Dosage, Side Effects, Interactions, Warning."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Prabhavalkar KS, Poovanpallil NB, Bhatt LK. Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Frontiers in Pharmacology. 2015","DOI":"10.3389\/fphar.2015.00242"},{"key":"ref47","unstructured":"Ghaffarpour M, Pakdaman H, Harirchian MH, Omrani H-AG, Ghabaee M, Zamani B et al. Pharmacokinetic and pharmacodynamic properties of the new AEDs: a review article. Iranian journal of neurology. 2013"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Rambeck B, Wolf P. Lamotrigine Clinical Pharmacokinetics. Clinical Pharmacokinetics. 1993","DOI":"10.2165\/00003088-199325060-00003"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1993","DOI":"10.2165\/00003495-199346010-00009"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Alabi A, Todd A, Husband A, Reilly J. Safety profile of lamotrigine in overdose. Therapeutic Advances in Psychopharmacology. 2016","DOI":"10.1177\/2045125316656707"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Aschenbrenner DS. New Warning for Lamotrigine. The American journal of nursing. 2018","DOI":"10.1097\/01.NAJ.0000544164.75186.5f"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW et al. HLA allele frequencies in 5802 koreans: varied allele types associated with SJS\/TEN according to culprit drugs. Yonsei Medical Journal. 2016;57(1):118\u2013126.","DOI":"10.3349\/ymj.2016.57.1.118"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. Hla. 2019;93(6):417\u2013435.","DOI":"10.1111\/tan.13530"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. International Journal of Dermatology. 2011;50(2):221\u2013224.","DOI":"10.1111\/j.1365-4632.2010.04745.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Deng Y, Li S, Zhang L, Jin H, Zou X. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure. 2018;60:163\u2013171.","DOI":"10.1016\/j.seizure.2018.06.024"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Shi YW, Min FL, Zhou D, Qin B, Wang J, Hu FY et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017;88(23):2183\u20132191.","DOI":"10.1212\/WNL.0000000000004008"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Hassan I. HLA-B*1502 screening in carbamazepine and lamotrigine candidates of Asian background. Australian and New Zealand Journal of Psychiatry. 2012;46(11):1106\u20131107.","DOI":"10.1177\/0004867412455702"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavi\u010diute D, Carrington M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New England Journal of Medicine. 2011;364(12):1134\u20131143.","DOI":"10.1056\/NEJMoa1013297"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human Molecular Genetics. 2011;20(5):1034\u20131041.","DOI":"10.1093\/hmg\/ddq537"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics Journal. 2014;14(3):281\u2013288.","DOI":"10.1038\/tpj.2013.40"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Yal\u00e7in B, Karaduman A. Stevens-Johnson syndrome associated with concomitant use of lamotrigine and valproic acid. Journal of the American Academy of Dermatology. 2000;43(5):898\u2013899.","DOI":"10.1067\/mjd.2000.100544"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez M, Maldonado C, Guevara N, Rey A, Fagiolino P, Carozzi A et al. Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome. Case Reports in Medicine. 2018:2018.","DOI":"10.1155\/2018\/5371854"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Kavitha S, Anbuchelvan T, Mahalakshmi V, Sathya R, Sabarinath TR, Gururaj N et al. Stevens-Johnson syndrome induced by a combination of lamotrigine and valproic acid. Journal of Pharmacy and Bioallied Sciences. 2015;7(6):S756\u2013S758.","DOI":"10.4103\/0975-7406.163545"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Shen Y-C, Chen S-J, Lin CCH, Chen C-H. Concomitant use of lamotrigine and aripiprazole increases risk of Stevens\u2013Johnson syndrome? International Clinical Psychopharmacology. 2007;22(4):247\u2013248.","DOI":"10.1097\/01.yic.0000224789.21406.81"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Kanner AM. When Thinking of Lamotrigine and Valproic Acid, Think \u201cPharmacokinetically\u201d! Epilepsy Currents. 2004;4(5):206\u2013207.","DOI":"10.1111\/j.1535-7597.2004.04515.x"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Guberman AH, Besag FMC, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM et al. Lamotrigine-associated rash: Risk\/benefit considerations in adults and children. Epilepsia. 1999;40(7):985\u2013991.","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Wang XQ, Lv B, Wang HF, Zhang X, Yu SY, Huang XS et al. Lamotrigine-induced severe cutaneous adverse reaction: update data from 1999\u20132014. Journal of Clinical Neuroscience. 2015;22(6):1005\u20131011.","DOI":"10.1016\/j.jocn.2015.01.016"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Schlienger RG, Shapiro LE, Shear NH. Lamotrighe-Induced Severe Cutaneous Adverse Reactions. Epilepsia. 1998;39(s7):S22\u2013S26.","DOI":"10.1111\/j.1528-1157.1998.tb01681.x"},{"key":"ref69","unstructured":"Sladden Mike, Mortimer Mike, Chave T. Australian Family Physician. 2004;33(10):829\u2013830. Cautionary tale \u2022 CLINICAL PRACTICE."},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Houser J, Graham A. Rechallenge of lamotrigine after development of rash. Mental Health Clinician. 2018;8(5):247\u2013249.","DOI":"10.9740\/mhc.2018.09.247"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:28:50Z","timestamp":1791314930000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/lamotrigine-and-stevens-johnson-syndrome-prevention\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4398","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}